Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease

Lisanna Sinisalu, View ORCID ProfilePartho Sen, View ORCID ProfileSamira Salihović, View ORCID ProfileSuvi M. Virtanen, View ORCID ProfileHeikki Hyöty, View ORCID ProfileJorma Ilonen, View ORCID ProfileJorma Toppari, View ORCID ProfileRiitta Veijola, View ORCID ProfileMatej Orešič, View ORCID ProfileMikael Knip, View ORCID ProfileTuulia Hyötyläinen
doi: https://doi.org/10.1101/2020.04.02.20051359
Lisanna Sinisalu
1School of Science and Technology, Örebro University, Örebro, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Partho Sen
2Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Partho Sen
Samira Salihović
1School of Science and Technology, Örebro University, Örebro, Sweden
3School of Medical Sciences, Örebro University, Örebro, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samira Salihović
Suvi M. Virtanen
4Finnish Institute for Health and Welfare, Public Health Promotion Unit, Helsinki, Helsinki, Finland; Unit of Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland; Tampere University Hospital, Research, Development and Innovation Center, Tampere, Finland; and Tampere Center for Child Health Research, Tampere University Hospital, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Suvi M. Virtanen
Heikki Hyöty
5Faculty of Medicine Health Technology, Tampere University, Tampere, Finland
6Fimlab Laboratories, Pirkanmaa Hospital District, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Heikki Hyöty
Jorma Ilonen
7Immunogenetics Laboratory, Institute of Biomedicine, University of Turku, Turku, Finland
8Clinical Microbiology, Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorma Ilonen
Jorma Toppari
9Institute of Biomedicine, Centre for Integrative Physiology and Pharmacology, and Centre for Population Health Research, University of Turku, Turku, Finland
10Department of Pediatrics, Turku University Hospital, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jorma Toppari
Riitta Veijola
11Department of Paediatrics, PEDEGO Research Unit, Medical Research Centre, University of Oulu, Oulu, Finland
12Department of Children and Adolescents, Oulu University Hospital, Oulu, Finland
13Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Riitta Veijola
Matej Orešič
2Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
3School of Medical Sciences, Örebro University, Örebro, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matej Orešič
  • For correspondence: matej.oresic@utu.fi mikael.knip@helsinki.fi tuulia.hyotylainen@oru.se
Mikael Knip
14Pediatric Research Center, Children’s Hospital, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland
15Center for Child Health Research, Tampere University Hospital, Tampere, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mikael Knip
  • For correspondence: matej.oresic@utu.fi mikael.knip@helsinki.fi tuulia.hyotylainen@oru.se
Tuulia Hyötyläinen
1School of Science and Technology, Örebro University, Örebro, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tuulia Hyötyläinen
  • For correspondence: matej.oresic@utu.fi mikael.knip@helsinki.fi tuulia.hyotylainen@oru.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

OBJECTIVES Celiac disease (CD) is a systemic immune-mediated disorder with increased frequency in the developed countries over the last decades implicating the potential causal role of various environmental triggers in addition to gluten. Herein, we apply determination of perfluorinated alkyl substances (PFAS) and combine the results with the determination of bile acids (BAs) and molecular lipids, with the aim to elucidate the impact of prenatal exposure on risk of progression to CD in a prospective series of children prior the first exposure to gluten (at birth and at 3 months of age).

METHODS We analyzed PFAS, BAs and lipidomic profiles in 76 plasma samples at birth and at 3 months of age in the Type 1 Diabetes Prediction and Prevention (DIPP) study (n=17 progressors to CD, n=16 healthy controls, HCs).

RESULTS Plasma PFAS levels showed a significant inverse association with the age of CD diagnosis in infants who later progressed to the disease. Associations between BAs and triacylglycerols (TGs) showed different patterns already at birth in CD progressors, indicative of different absorption of lipids in these infants.

DISCUSSION PFAS exposure may modulate lipid and BA metabolism, and the impact is different in the infants who develop CD later in life, in comparison to HCs. The results indicate more efficient uptake of PFAS in such infants. Higher PFAS exposure during prenatal and early life may accelerate the progression to CD in the genetically predisposed children.

WHAT IS KNOWN Several observational studies have implicated a role of early life environmental triggers other than gluten in the development of CD. This is supported by the findings showing dysregulation of lipids already prior to the first introduction of gluten.

WHAT IS NEW HERE We show that prenatal exposure to perfluorinated compounds is associated with changes in the lipid metabolism, most likely through the bile acids, and that a high exposure during prenatal and early life may accelerate the progression to CD in the genetically predisposed children.

TRANSLATIONAL IMPACT Exposure to environmental chemicals may impact the rate of progression to CD and should be assessed as a potential risk factor of CD in larger clinical cohort settings.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by funding from Vetenskapsrådet (to T.H.; grant no. 2016-05176) and Formas (to T.H. and M.O.; grant no. 2019-00869). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The lipidomics data sets and the clinical metadata generated in this study are available from MetaboLights, under accession number MTBLS729.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted April 15, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease
Lisanna Sinisalu, Partho Sen, Samira Salihović, Suvi M. Virtanen, Heikki Hyöty, Jorma Ilonen, Jorma Toppari, Riitta Veijola, Matej Orešič, Mikael Knip, Tuulia Hyötyläinen
medRxiv 2020.04.02.20051359; doi: https://doi.org/10.1101/2020.04.02.20051359
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Early-life exposure to perfluorinated alkyl substances modulates lipid metabolism in progression to celiac disease
Lisanna Sinisalu, Partho Sen, Samira Salihović, Suvi M. Virtanen, Heikki Hyöty, Jorma Ilonen, Jorma Toppari, Riitta Veijola, Matej Orešič, Mikael Knip, Tuulia Hyötyläinen
medRxiv 2020.04.02.20051359; doi: https://doi.org/10.1101/2020.04.02.20051359

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (214)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1090)
  • Dentistry and Oral Medicine (194)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (497)
  • Epidemiology (9744)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2298)
  • Geriatric Medicine (221)
  • Health Economics (461)
  • Health Informatics (1548)
  • Health Policy (729)
  • Health Systems and Quality Improvement (600)
  • Hematology (236)
  • HIV/AIDS (500)
  • Infectious Diseases (except HIV/AIDS) (11618)
  • Intensive Care and Critical Care Medicine (615)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2136)
  • Nursing (133)
  • Nutrition (332)
  • Obstetrics and Gynecology (424)
  • Occupational and Environmental Health (516)
  • Oncology (1171)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (144)
  • Palliative Medicine (50)
  • Pathology (308)
  • Pediatrics (692)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2168)
  • Public and Global Health (4640)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (450)
  • Respiratory Medicine (621)
  • Rheumatology (273)
  • Sexual and Reproductive Health (224)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (42)
  • Transplantation (120)
  • Urology (94)